Comparative Pharmacology
Head-to-head clinical analysis: NUTROPIN AQ versus SEROSTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTROPIN AQ versus SEROSTIM.
NUTROPIN AQ vs SEROSTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptor, activating JAK2/STAT5 signaling pathway, leading to increased IGF-1 production and linear growth.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
0.006 mg/kg subcutaneously once daily.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
None Documented
None Documented
Terminal half-life: 2.5-3.0 hours for subcutaneous administration. Clinical context: Supports once-daily dosing; levels return to baseline by 12-16 hours post-dose.
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Renal: >99% of administered dose excreted via kidneys as intact growth hormone and metabolites. Biliary/fecal: negligible (<1%).
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Category C
Category C
Growth Hormone
Growth Hormone